Integrity Applications, Inc.: Integrity Applications Issues Shareholder Update Letter
Dear Fellow Shareholders,
2020 was an important operational year for the Company, even in light of the widespread effects of the COVID-19 pandemic. We hope all of you have stayed healthy and safe during these difficult times. This pandemic has exposed the need for the adoption of innovative digital health technologies for chronic diseases and we believe more than ever that the GlucoTrack platform that we are building will be well suited for addressing the critical market need as it relates to those suffering with diabetes and prediabetes.
Talent development, recruiting and organizational health have been a critical focus of the Company over the last 12 months. We are thrilled to have attracted high-quality individuals to the Company, each of whom bring extensive experience in their respective fields. We have bolstered our Senior Management with the recruitment of Erez Ben-Zvi, a highly experienced MedTech development professional who joined us last year as Vice President of Product, and recently took on the additional role of General Manager, and Shalom Shushan, a seasoned executive who joined us as Chief Technology Officer. Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at DexCom and MiniMed, joined our board of directors. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Yair Briman, the former CEO of Philips Healthcare Informatics, Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert currently at Samsung Health and formerly of Dexcom, and Dr. Alexander Raykhman PhD, a measurement and artificial intelligence expert. We intend to continue to invest in our talent and to expand and strengthen all areas within the company.